Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Aggrastat)
1,723 results
  • An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives. [Review]
    High Blood Press Cardiovasc Prev. 2023 Jan 13 [Online ahead of print]Sharifi-Rad J, Sharopov F, … Calina D
  • The glycoprotein (GP) IIb/IIIa receptor is found integrin present in platelet aggregations. GP IIb/IIIa antagonists interfere with platelet cross-linking and platelet-derived thrombus formation through the competition with fibrinogen and von Willebrand factor. Currently, three parenteral GP IIb/IIIa competitors (tirofiban, eptifibatide, and abciximab) are approved for clinical use in patients aff…
  • Platelet-Mimicking Nanosponges for Functional Reversal of Antiplatelet Agents. [Journal Article]
    Circ Res. 2023 Jan 10 [Online ahead of print]Xu J, Yan N, … Nie G
  • During long-term antiplatelet agents (APAs) administration, patients with thrombotic diseases take a fairly high risk of life-threatening bleeding, especially when in need of urgent surgery. Rapid functional reversal of APAs remains an issue yet to be efficiently resolved by far due to the lack of any specific reversal agent in the clinic, which greatly restricts the use of APAs. Although platele…
  • Analysis of risk factors for the efficacy of tirofiban in the treatment of acute ischemic stroke. [Journal Article]
    Neurol Res. 2023 Jan 04 [Online ahead of print]Liu C, Yin L, … Hou Y
  • CONCLUSIONS: The early curative effect of tirofiban in acute ischemic stroke patients with a heavy drinking history and elevated total cholesterol was poor. In patients with acute ischemic stroke, the higher the NIHSS score was within a certain range (8 < NIHSS ≤15 and the Org 10,172 Trial in the Treatment of Acute Stroke (TOAST) belongs to small-artery occlusion lacunar) at the initiation of treatment and the shorter the time from onset to treatment, the better the early curative effect was.
  • Targeting integrin pathways: mechanisms and advances in therapy. [Review]
    Signal Transduct Target Ther. 2023 Jan 02; 8(1):1.Pang X, He X, … Cui Y
  • Integrins are considered the main cell-adhesion transmembrane receptors that play multifaceted roles as extracellular matrix (ECM)-cytoskeletal linkers and transducers in biochemical and mechanical signals between cells and their environment in a wide range of states in health and diseases. Integrin functions are dependable on a delicate balance between active and inactive status via multiple mec…
  • [Role of platelets aggregation in the process of ductus arteriosus closure of newborn pups]. [Journal Article]
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022 Nov; 34(11):1194-1199.Ren Y, Gao X, … Su M
  • CONCLUSIONS: The ductus arteriosus of newborn pups begin to close 1-4 hours after birth, and all closed at 12 hours after birth. The expression of platelet membrane GPIIb-IIIa in ductus arteriosus increase gradually after birth, and the platelet aggregation may participate in and promote ductus arteriosus closure to some extent. Tirofiban, a platelet membrane GPIIb-IIIa receptor antagonist, may delay ductus arteriosus closure of newborn pups to some extent by inhibiting platelet aggregation.
  • Anti-platelet peptides targeting αIIbβ3 outside-in signaling pathway [Journal Article]
    Curr Protein Pept Sci. 2022 11 14 [Online ahead of print]Wang J, Xu X
  • Platelets and their progenitors express high levels of integrin αIIbβ3, which plays a key role in platelet functions, hemostasis, and arterial thrombosis. Because of their quick and high efficacy, the three anti-αIIbβ3 drugs, abciximab, eptifibatide, and tirofiban, are regarded as potent anti-thrombotics and clinically approved by US Food and Drug Administration. However, because they interfere w…
  • Prospective pilot study of tirofiban in progressive stroke after intravenous thrombolysis. [Journal Article]
    Front Neurol. 2022; 13:982684.Zhang Y, Wang J, … Liu Y
  • CONCLUSIONS: Early treatment with low-dose tirofiban in AIS patients with neurologic deterioration after IVT potentially improved functional recovery and attenuated neurologic deficits as early as 7 days and did not increase the risk of various hemorrhagic complications. However, the therapeutic efficacy of tirofiban treatment in END patients needs to be determined by future randomized clinical trials with a large study population.
New Search Next